PURPOSE: @entity320 ( @entity320 ) is an ocular surface @entity5 that can lead to fatal @entity3 . @entity1 developing, @entity5 -associated lymphangiogenesis have a significantly increased risk of @entity3 , because @entity5 spread primarily occurs via lymphatic vessels to the draining lymph node. Here, we describe a novel immune-competent @entity19 model of @entity320 that displays @entity5 -associated lymphangiogenesis with development of @entity3 . METHODS: C57BL/6 @entity19 received C57BL/6N-derived dermal @entity320 cells ( @entity13765 [ @entity13765 ] @entity11953 [ @entity11953 ]+) or B16F10 via subconjunctival injection. A clinical score quantified primary @entity5 growth and @entity3 were identified by macroscopic examination of the draining lymph nodes, lung, and spleen. @entity5 and @entity3 was achieved by immunohistochemical staining for markers of pigmented cells ( @entity27828 [ @entity27828 ]) and S-100, and of cell proliferation (Ki67). The intra- and peritumoral @entity5231 + blood and @entity14530 ( @entity14530 )+ lymphatic vessels were quantified immunohistochemically. RESULTS: All @entity19 rapidly developed aggressive @entity27828 +, S100+, and Ki67+ @entity320 . @entity3 were found in the lymph node (9%) and lung (6%) of @entity13765 - @entity11953 R24C-treated @entity19 and in the spleen (8%) and lung (17%) of B16F10-treated @entity19 . The amount of peri- and intratumoral blood vessels was significantly increased compared with lymphatic vessels. CONCLUSIONS: This @entity320 model in immune-competent animals offers new possibilities to study the pathobiology of @entity5 growth, invasion, and mechanisms of @entity3 spread, and provides a robust model to explore new immune-based and antilymphangiogenic treatment modalities of this malignancy.

A Novel Model of Metastatic XXXX in Immune-Competent @entity19 .

@entity1 :: ('9606', 'Species') :: ['Patients'] @entity13765 :: ('15234(Tax:10090)', 'Gene') :: ['hepatocyte growth factor', 'HGF'] @entity14530 :: ('114332(Tax:10090)', 'Gene') :: ['LYVE-1', 'lymphatic vessel endothelium hyaluronan receptor-1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Confirmation of tumors'] @entity19 :: ('10090', 'Species') :: ['mice', 'N mice', 'mouse'] @entity27828 :: ('13190(Tax:10090)', 'Gene') :: ['TRP2', 'tyrosinase related protein-2'] @entity11953 :: ('12567(Tax:10090)', 'Gene') :: ['Cdk4', 'cyclin dependent kinase-4'] @entity5231 :: ('18613(Tax:10090)', 'Gene') :: ['CD31'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumor', 'metastases', 'metastatic tumors', 'Metastatic tumors', 'metastatic disease'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'Conjunctival melanoma', 'CM']
@entity320 :: (MESH:D008545,Disease) :: ['Conjunctival Melanoma']
